PATH
🇺🇸United States
Micron Biomedical Advances Needle-Free Vaccine Technology with $43 Million in Funding
• Micron Biomedical has secured $43 million in total grant funding, including a recent $7.5 million grant from the Bill & Melinda Gates Foundation to support measles-rubella vaccine development and manufacturing scale-up.
• The company's innovative dissolvable microarray technology allows painless, needle-free delivery of vaccines through the skin, potentially eliminating cold chain requirements and enabling administration by non-clinicians.
• Recent clinical trials published in The Lancet demonstrated the technology safely immunized children as young as 9 months against measles and rubella, with the company now preparing for the world's first Phase 2 trial of needle-free vaccine technology in infants.
WHO Approves Single-Dose Cecolin HPV Vaccine Following Landmark Trial
• The WHO has approved Cecolin, a bivalent HPV vaccine, for single-dose use, potentially revolutionizing cervical cancer prevention efforts globally.
• A clinical trial (CVIA 087) conducted by icddr,b and partners demonstrated the safety and efficacy of single-dose Cecolin vaccination.
• The approval aims to address vaccine supply challenges and improve access in low- and middle-income countries, where 90% of cervical cancer deaths occur.
• Health officials urge vaccination for girls aged 10-14, highlighting it as a critical opportunity to protect against HPV-related cervical cancer.
© Copyright 2025. All Rights Reserved by MedPath